April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
African Descent and Glaucoma Evaluation Study (ADAGES): Racial Differences in Rates of Progressive Visual Field Loss in Glaucoma
Felipe A. Medeiros; Mauro Leite; Linda M. Zangwill; Robert N. Weinreb; Jeffrey M. Liebmann; Pamela A. Sample; Christopher A. Girkin
Author Affiliations & Notes
  • Felipe A. Medeiros
    Ophthalmology, Univ of California-San Diego, La Jolla, California
  • Mauro Leite
    Ophthalmology, Univ of California-San Diego, La Jolla, California
  • Linda M. Zangwill
    Ophthalmology, Univ of California-San Diego, La Jolla, California
  • Robert N. Weinreb
    Ophthalmology, Univ of California-San Diego, La Jolla, California
  • Jeffrey M. Liebmann
    Ophthalmology, New York Eye and Ear Informary, New York University School of Medicine, New York, New York
  • Pamela A. Sample
    Ophthalmology, Univ of California-San Diego, La Jolla, California
  • Christopher A. Girkin
    Ophthalmology, School of Medicine, University of Alabama, Birmingham, Alabama
  • Footnotes
    Commercial Relationships  Felipe A. Medeiros, Alcon, Inc. (F, C), Allergan, Inc. (C), Carl-Zeiss Meditec (F), Merck, Inc. (F), Pfizer, Inc. (F), Reichert, Inc (F); Mauro Leite, None; Linda M. Zangwill, Carl-Zeiss Meditec, Inc. (F), Heidelberg Engineering, GmBH (F, R), Optovue, Inc. (F), Topcon Medical Systems, Inc. (F); Robert N. Weinreb, Alcon, Inc. (C), Allergan, Inc. (C), Carl-Zeiss Meditec, Inc. (F, C), Heidelberg Engineering, GmBH (F), Merck, Inc. (C), Novartis, Inc. (F), Optovue, Inc. (F), Pfizer, Inc. (C), Topcon Medical Systems, Inc. (F); Jeffrey M. Liebmann, Alcon, Inc. (C), Allergan, Inc. (C), Carl-Zeiss Meditec, Inc. (F), Dyopsis Corp. (F, C), Heidelberg Engineering, GmBH (F), Optovue, Inc. (F, C), Pfizer, Inc. (C), Topcon Medical Systems, Inc. (F, C); Pamela A. Sample, Carl-Zeiss Meditec, Inc. (F), Haag-Streit, Inc. (F); Christopher A. Girkin, Alcon, Inc. (C), Allergan, Inc. (C), Carl-Zeiss Meditec, Inc. (R), Heidelberg Engineering, GmBH (R), Merck, Inc. (R), Optovue, Inc. (R), Pfier, Inc. (C), Topcon Medical Systems, Inc. (R)
  • Footnotes
    Support  Supported by National Eye Institute grants U10EY14267, EY019869, and EY08208, EY11008, and EY13959 and Eyesight Foundation of Alabama; Alcon Laboratories Inc.; Allergan Inc.; Pfizer Inc.; Merck Inc.;
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2117. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      African Descent and Glaucoma Evaluation Study (ADAGES): Racial Differences in Rates of Progressive Visual Field Loss in Glaucoma
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Felipe A. Medeiros, Mauro Leite, Linda M. Zangwill, Robert N. Weinreb, Jeffrey M. Liebmann, Pamela A. Sample, Christopher A. Girkin; African Descent and Glaucoma Evaluation Study (ADAGES): Racial Differences in Rates of Progressive Visual Field Loss in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2117.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate and compare rates of progressive visual field loss in a cohort of African Descent (AD) and European Descent (ED) patients diagnosed with glaucoma or suspected of having the disease.

Methods: : This was an observational cohort study including 895 eyes of 520 patients (222 AD and 298 ED) with glaucoma or suspected of disease recruited from the Diagnostic Innovations in Glaucoma Study (DIGS) and the African Descent and Glaucoma Study (ADAGES). Included eyes had to have at least 5 standard automated perimetry visual fields (SITA 24-2 strategy) and a minimum follow-up period of 2 years. Random coefficient models were used to evaluate the association between race and rates of visual field progression, as assessed by Mean Deviation (MD) and the Visual Field Index (VFI). Additionally, quantile regression was performed to evaluate the relationship between race and presence of fast visual field progression during follow-up.

Results: : Patients were followed for an average of 5.1 ± 1.3 years. The median number of visual fields available during follow-up was 8 (IQR: 6-10). There was no significant difference between mean rates of visual field progression in AD and ED (-0.06dB/year vs. -0.04dB/year; P = 0.626). An analysis of the racial differences in the quantiles of the distributions of slopes of change, however, revealed that the AD group had a significantly higher proportion of eyes with fast progression. The 5th quantile of rates of change in AD was -0.62dB/year compared to -0.35dB/year in ED, respectively (P <0.001). For the 1st quantile, the corresponding numbers were -1.33dB/year vs. -0.65dB/year (P = 0.021). Differences between the two racial groups remained significant after adjustment for age, baseline disease severity, mean intraocular pressure during follow-up and central corneal thickness. Similar results were obtained when rates of VFI change were analyzed.

Conclusions: : A significantly higher proportion of AD patients showed fast rates of progression compared to ED participants, suggesting that the AD population may be at significantly higher risk for development of functional impairment from glaucoma.

Clinical Trial: : http://www.clinicaltrials.gov NCT00221923

Keywords: visual fields • clinical (human) or epidemiologic studies: risk factor assessment • optic nerve 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept